- Summit will highlight 100+ leading technology firms in the international cannabinoid-derived pharmaceuticals space; more than 3,500 investors are expected to attend
- LXRP is a drug delivery platform innovator with a growing IP portfolio of 10 patents granted and more than 50 patents filed globally
- LXRP out-licenses its delivery technology, such as its proprietary DehydraTECH; it holds a patent for oral delivery of all cannabinoids
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), a drug delivery platform innovator, will exhibit at the Cantech Investment Conference 2019, taking place on January 29-30 in Toronto, and it will participate in a specialized event where it will meet technology investors. Cantech (http://ibn.fm/KFZid) will feature an analysis of cannabis edibles, as well as a presentation on cannabis medical applications and R&D (http://ibn.fm/JKfiB).
Based in British Columbia, Canada, LXRP is a biotechnology company focused on out-licensing its disruptive delivery technology, which promotes healthier ingestion methods. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio. DehydraTECH is its absorption technology platform.
LXRP has aggressive expansion plans for 2019, having recently announced the addition of key personnel, with a special focus on its lab R&D activities (http://ibn.fm/j33eq). LXRP already has 10 patents granted in the U.S. and Australia and has filed for more than 50 patents worldwide across 10 patent families.
For more information, visit the company’s website at www.LexariaBioscience.com
